StockData
Petros Pharmaceuticals, Inc. logo

Petros Pharmaceuticals, Inc. (PTPI) shareholders

PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$0.00+0.00 (+5.56%)

Close on Oct 19, 2026Market cap $135.07KP/E –Yield –

Ownership

Who owns Petros Pharmaceuticals's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Iroquois Capital Management, LLC
Joint filing with Richard Abbe (9.99%), Kimberly Page (9.99%)
5,939,9549.99%13G (passive) amendmentMar 31, 2025
Richard Abbe
Joint filing with Iroquois Capital Management, LLC (9.99%), Kimberly Page (9.99%)
4,434,7739.99%13G (passive) amendmentDec 21, 2025
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
Joint filing with Ayrton Capital LLC (6.20%), Waqas Khatri (6.20%)
657,6146.20%13G (passive) amendmentDec 31, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Robert WeinsteinChief Accounting Officer636,0041.50%Jun 25, 2026
Fady BoctorSee Remarks894,9862.11%Jun 5, 2026
Mitchell ArnoldSee Remarks150,3900.35%Feb 21, 2025
Wayne Remell WalkerDirector881,3332.08%Jun 8, 2026
Joshua SilvermanDirector8,790,45020.75%Jun 5, 2026
Bruce BernsteinDirector3,762,3348.88%Jun 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Wayne Remell Walker
Director
Jun 5, 2026Award+375,000––881,333
Bruce Bernstein
Director
Jun 5, 2026Award+1,875,000––3,762,334
Fady Boctor
See Remarks
Jun 5, 2026Award+375,000––894,986
Joshua Silverman
Director
Jun 5, 2026Award+4,375,000––8,790,450
Fady Boctor
See Remarks
Jan 2, 2026Award+500,000––519,986
Joshua Silverman
Director
Jan 2, 2026Award+4,375,000––4,415,450
Wayne Remell Walker
Director
Jan 2, 2026Award+500,000––506,333
Bruce Bernstein
Director
Jan 2, 2026Award+1,875,000––1,887,334
Mitchell Arnold
See Remarks
Feb 19, 2025Award+150,000––150,000
Fady Boctor
See Remarks
Feb 19, 2025Award+450,000––499,645
Wayne Remell Walker
Director
Feb 19, 2025Award+150,000––158,314
Joshua Silverman
Director
Feb 19, 2025Award+1,000,000––1,011,237
Bruce Bernstein
Director
Feb 19, 2025Award+300,000––308,346
Fady Boctor
See Remarks
Dec 21, 2023Award+49,645––49,645
Bruce Bernstein
Director
Apr 26, 2023Option exercise+6,050––8,346
Wayne Remell Walker
Director
Apr 26, 2023Option exercise+6,050––8,314
Joshua Silverman
Director
Apr 26, 2023Option exercise+6,722––11,237
Greg Bradley
Director
Apr 26, 2023Option exercise+6,050––8,314
Wayne Remell Walker
Director
Jan 20, 2023Option exercise+2,264––2,264
Bruce Bernstein
Director
Jan 20, 2023Option exercise+2,264––2,296
Joshua Silverman
Director
Jan 20, 2023Option exercise+2,515––4,515
Greg Bradley
Director
Jan 20, 2023Option exercise+2,264––2,264
Juggernaut Partners III GP, L.P.
10% owner
Dec 22, 2021Buy+145,773$3.43$500.00K5,703,544
Juggernaut Partners III GP, Ltd.
10% owner
Nov 29, 2021Buy+500,000$3.00$1.50M5,557,771
John D. Shulman
Director, 10% owner
Oct 18, 2021Buy+1,661,807$1.72$2.86M5,057,771
Juggernaut Partners III GP, L.P.
10% owner
Dec 1, 2020Award+3,395,964––3,395,964
Keith Lavan
Chief Financial Officer
Dec 1, 2020Award+975––975
Andrew Gesek
President, Timm Medical
Dec 1, 2020Award+97––97
John D. Shulman
Director, 10% owner
Dec 1, 2020Award+3,382,416––3,382,416
Joshua Silverman
Director
Dec 1, 2020Award+20,000––20,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+47.5%
From 0M shares
Short volume, 20 days
56.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Petros Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2 shares on Sep 17, 2026 over the last 90 days.

See a number that looks wrong?